CARTsejtterápia

CARTsejtterápia, also known as CAR T-cell therapy, is an innovative treatment approach used in the field of oncology, particularly for certain types of cancer. The therapy involves the extraction of a patient's T-cells, which are then genetically modified in a laboratory to produce chimeric antigen receptors (CARs). These CARs are designed to recognize and bind to specific antigens on cancer cells, enabling the modified T-cells to target and destroy the cancer cells more effectively.

The process begins with the collection of the patient's peripheral blood mononuclear cells (PBMCs), which contain T-cells. These cells are then isolated and cultured in a laboratory. Using genetic engineering techniques, the T-cells are modified to express CARs that are specific to the cancer antigen of interest. The modified T-cells are then expanded in culture to create a large population of CAR T-cells.

Once the CAR T-cells have been generated, they are infused back into the patient. The infused CAR T-cells migrate to the sites of cancer and, upon recognizing the cancer-specific antigens, initiate an immune response. This response leads to the activation and proliferation of the CAR T-cells, which then destroy the cancer cells. The therapy aims to induce a durable and complete response, potentially leading to long-term remission or even cure of the cancer.

CARTsejtterápia has shown promising results in the treatment of certain hematological malignancies, such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). However, the therapy is still in the early stages of development, and its long-term efficacy and safety are being actively investigated. Research is ongoing to optimize the design of CARs, improve the manufacturing processes, and expand the range of cancers that can be effectively treated with CAR T-cell therapy.